Pacritinib (SB1518)
Important Notice: For research use only. We do not sell to patients.
Not your Region? View all Distributors
Important Notice: For research use only. We do not sell to patients.
Not your Region? View all Distributors
Discription | Pacritinib, also known as SB1518, is an orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Pacritinib competes with JAK2 for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, and so caspase-dependent apoptosis. | ||
---|---|---|---|
Targets |
|
Catalog Num | A12694 |
---|---|
Formula | C28H32N4O3 |
Molecular Weight | 472.58 |
CAS Number | 937272-79-2 |
SMILES | C1CCN(C1)CCOC2=C3COC/C=C/COCC4=CC=CC(=C4)C5=NC(=NC=C5)NC(=C3)C=C2 |
Synonyms | SB-1518; SB 1518 |
Storage | Store lyophilized at -20ºC, keep desiccated. |
In vitro | DMSO | Warmed: 10 mg/mL (21.15 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 21.16 mL | 105.8 mL | 211.6 mL |
0.5 mM | 4.23 mL | 21.16 mL | 42.32 mL |
1 mM | 2.12 mL | 10.58 mL | 21.16 mL |
5 mM | 0.42 mL | 2.12 mL | 4.23 mL |
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2